ALXN Alexion Pharmaceuticals Inc.

112.44
-0.03  -0%
Previous Close 112.47
Open 112.82
Price To Book 2.4
Market Cap 24,881,925,296
Shares 221,290,691
Volume 271,468
Short Ratio
Av. Daily Volume 1,757,456
Stock charts supplied by TradingView

NewsSee all news

  1. François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

  2. Alexion Issues Statement on Path to Value Creation

    Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today issued the following statement on behalf of the Board of Directors and management team: "The Board and management team are focused on delivering long-term

  3. Alexion to Present at the 2019 Evercore ISI HealthCONx

    Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that management will present at the 2019 Evercore ISI HealthCONx in Boston, MA on Tuesday, December 3rd, 2019 at 8:45 a.m. ET. An audio webcast of the presentation

  4. SOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

    - SOLIRIS® (eculizumab) is the first and only approved medication for NMOSD in Japan - - 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63% receiving

  5. Alexion to Present at the 2019 Stifel Healthcare Conference

    Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that management will present at the 2019 Stifel Healthcare Conference in New York, NY on Tuesday, November 19th, 2019 at 8:35 a.m. ET. An audio webcast of the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b/3 trial to be initiated 1H 2020 with data due in 2021.
CAEL‐101
AL amyloidosis
Phase 2 completion due 2020.
ACH-4471
C3 glomerulopathy (C3G)
FDA Approval announced June 27, 2019.
Eculizumab
Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)
FDA Approval announced October 18, 2019.
ULTOMIRIS (ravulizumab-cwvz)
atypical Hemolytic Uremic Syndrome (aHUS)
FDA approval announced December 21, 2018.
ULTOMIRIS (ravulizumab-cwvz)
Paroxysmal nocturnal hemoglobinuria (PNH)
Approval announced October 23, 2017.
Eculizumab
Refractory generalized myasthenia gravis (gMG)
Phase 3 trial to be initiated early 2020.
Danicopan (ACH-4471)
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 2 trial planned to commence 1H 2020.
ACH-5228
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 3 top-line data due 1H 2021.
ALXN1840 (WTX101)
Wilson disease
Phase 3 trial initiated 1Q 2019.
ULTOMIRIS (ravulizumab-cwvz)
Generalized myasthenia gravis (gMG)
Phase 2/3 trial to be initiated early 2020.
ALXN1830
Warm autoimmune hemolytic anemia (WAIHA)
Phase 3 PK data due 1H 2020.
ULTOMIRIS (ravulizumab-cwvz) subcutaneous
Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS)
Phase 2 trial did not meet primary endpoint. Phase 3 trial planned for 2020.
Elamipretide
Leber’s hereditary optic neuropathy (LHON)
Phase 3 data due January 2020.
Elamipretide
Primary mitochondrial myopathy
Phase 3 trial to commence 1H 2020.
ULTOMIRIS
Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA)
Phase 3 trial has commenced - noted October 23, 2019.
Eculizumab
Generalized myasthenia gravis (gMG) - children
Phase 3 trial to commence by the end of 2019.
Eculizumab
Neuromyelitis Optica Spectrum Disorder (NMOSD) - children

Latest News

  1. François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

  2. Alexion Issues Statement on Path to Value Creation

    Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today issued the following statement on behalf of the Board of Directors and management team: "The Board and management team are focused on delivering long-term

  3. Alexion to Present at the 2019 Evercore ISI HealthCONx

    Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that management will present at the 2019 Evercore ISI HealthCONx in Boston, MA on Tuesday, December 3rd, 2019 at 8:45 a.m. ET. An audio webcast of the presentation

  4. SOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

    - SOLIRIS® (eculizumab) is the first and only approved medication for NMOSD in Japan - - 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63% receiving

  5. Alexion to Present at the 2019 Stifel Healthcare Conference

    Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that management will present at the 2019 Stifel Healthcare Conference in New York, NY on Tuesday, November 19th, 2019 at 8:35 a.m. ET. An audio webcast of the

  6. Fortress Biotech Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

    NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and

  7. Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    – Reached an agreement to be acquired by Alexion; transaction expected to close in first half of 2020 – – Danicopan (ACH-4471) received Breakthrough Therapy designation for treatment of PNH; Phase 2

  8. Alexion Announces Data Presentations at 61st American Society of Hematology Annual Meeting

    - Accepted abstracts include presentations of ULTOMIRIS® (ravulizumab-cwvz) Phase 3 PNH data through 52 weeks - - ULTOMIRIS is the first and only long-acting C5 complement inhibitor, now available in the U.S. for the

  9. Alexion Receives FDA Approval for ULTOMIRIS® (ravulizumab-cwvz) for Atypical Hemolytic Uremic Syndrome (aHUS)

    - At 26 weeks, 54% of adults and 71% of children treated with ULTOMIRIS demonstrated Complete Thrombotic Microangiopathy (TMA) Response - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.S. Food

  10. Alexion Announces Appointment of Tanisha Carino, Ph.D., as Chief Corporate Affairs Officer

    - Dr. Carino to head up newly integrated Corporate Affairs function including global government affairs, public policy and communications - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the appointment of

  11. Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases

    - Elamipretide in Phase 3 development for primary mitochondrial myopathy - - If option is exercised, Alexion & Stealth will co-develop and co-promote subcutaneous elamipretide in U.S. & Alexion will receive

  12. Alexion to Report Third Quarter 2019 Results On Wednesday, October 23, 2019

    Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2019 before the US financial markets open on October 23, 2019. Following

  13. Alexion Announces CFO Succession

    - Aradhana Sarin, M.D., to become CFO after filing of Q3 2019 results - - Paul Clancy to step down as CFO and serve as senior advisor through mid-2020 - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced

  14. Alexion and BridgeBio Announce Japanese License Agreement for Eidos' Transthyretin Amyloidosis (ATTR) Investigational Medicine

    - Eidos grants Alexion exclusive license to develop and commercialize AG10 in Japan - - Phase 3 study of AG10 in ATTR cardiomyopathy underway in U.S. & Europe; Phase 3 trial in ATTR polyneuropathy planned to

  15. Alexion to Present at the 17th Annual Morgan Stanley Global Healthcare Conference

    Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that management will present at the 17th Annual Morgan Stanley Global Healthcare Conference in New York, NY on Monday, September 9th, 2019 at 8:45 a.m. ET. An

  16. Alexion Announces Upcoming Data Presentations at 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

    - Five abstracts accepted, including new long-term data from PREVENT trial of SOLIRIS® (eculizumab) in adults with anti-AQP4 antibody-positive NMOSD - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that

  17. Alexion to Present at the 14th Annual Citi Biotech Conference

    Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that management will present at the 14th Annual Citi Biotech Conference in Boston, MA on Wednesday, September 4th, 2019 at 12:00 p.m., ET. An audio webcast of the

  18. European Commission Approves SOLIRIS® (eculizumab) For the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)

     - SOLIRIS® (eculizumab) is the first and only approved medication for NMOSD in Europe - - 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63%

  19. European Commission Approves SOLIRIS® (eculizumab) For the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)

     - SOLIRIS® (eculizumab) is the first and only approved medication for NMOSD in Europe - - 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63%